



Robert Greene Sterne Edward J. Kessler Jorge A. Goldstein David K.S. Cornwell Robert W. Esmond Tracy-Gene G. Durkin Michele A. Cimbala Michael B. Ray Robert E. Sokohl Fric K. Steffe Michael Q. Lee Steven R. Ludwig Steven R. Ludwig John M. Covert Linda E. Alcorn Robert C. Millonig Donald J. Featherstone Timothy J. Shea, Jr Michael V. Messinger Judith II. Kim Judith U. Kim

Patrick E. Garrett Jeffrey T. Helvey Heidi L. Kraus Eldora L. Ellison Thomas C. Fiala Albert L. Ferro Donald R. Banowit Ponald R. Banowit Peter A. Jackman Jeffrey S. Weaver Kendrick P. Patterson Vincent L. Capuano Brian J. Del Buono Virgil Lee Beaston Theodore A. Wood Elizabeth J. Haanes Joseph S. Ostroff Frank R. Cottingham Rae Lynn P. Guest Daniel A. Klein

August 26, 2005

Jason D. Eisenberg Michael D. Specht Andrea J. Kamage Tracy L. Muller Jon E. Wright LuAnne M. DeSantis Ann E. Summerfield Helene C. Carlson Ted J. Ebersole Laura A. Vogel Michael J. Mancuso Bryan S. Wade Aaron L. Schwartz

Helene C. Carlson Cynthia M. Bouchez Timothy A. Doyle Gaby L. Longsworth Lori A. Gordon Nicole D. Dretar

Shannon A. Carroll* Wesley W. Jones* Matthew E. Kelley* Michelle K. Holoubeks

Registered Patent Agents • Karen R. Markowicz Nancy J. Leith Matthew J. Dowd Katrina Yujian Pei Quach Bryan L. Skelton Robert A. Schwartzman Teresa A. Colella Victoria S. Rutherford Simon J. Elliott Julie A. Heider Mita Mukherjee

Scott M. Woodhouse Christopher J. Walsh Liliana Di Nola-Baron Peter A. Socarras Jeffrey Mills

Of Counsel Kenneth C. Bass III Marvin C. Guthrie

*Admitted only in Maryland * Admitted only in Virginia Practice Limited to Federal Agencies

WRITER'S DIRECT NUMBER: (202) 772-8858 INTERNET ADDRESS: JHEIDER@SKGF.COM

PO Box 1450 Alexandria, VA 22313-1450

Commissioner for Patents

Art Unit 1645

Re: U.S. Utility Patent Application

Application No. 10/658,688; Filed: September 10, 2003

Codon-Optimized Polynucleotide-Based Vaccines Against Bacillus

anthracis Infection

Inventor: Gary G. HERMANSON Our Ref: 1530.0460002/EJH/J-H

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. First Supplemental Information Disclosure Statement;
- Form PTO-SB/08A, 1 page, listing 2 documents (US1 and US2);
- 3. Form PTO-SB/08B, 1 page, listing 4 documents (NPL1, NPL2, NPL3, and NPL4);
- 4. One (1) copy of the 3 cited documents (NPL1, NPL2, and NPL4); and
- 5. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents August 26, 2005 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

A STATE OF THE PARTY OF THE PAR

Julie A. Heider

Agent for Applicant Registration No. 54,161

EJH/J-H/tis Enclosures

425759v1

Sterne, Kessler, Goldstein & Fox PLLC.: 1100 New York Avenue, NW: Washington, DC 20005: 202.371.2600 f 202.371.2540: www.skgf.com

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Gary G. Hermanson AUG 2 6 2005

Appl. No.: 10/658,688

Filed: September 10, 2003

For: Codon-Optimized Polynucleotide-

Based Vaccines Against Bacillus

anthracis Infection

Confirmation No.: 3461

Art Unit: 1645

Examiner: Baskar, P.

Atty. Docket: 1530.0460002/EJH/J-H

First Supplemental Information Disclosure Statement Filing Under Under 37 C.F.R. § 1.97(b)

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450 Sir:

Listed on accompanying Form PTO-SB/08A and Form PTO/SB/08B are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. Copies of documents NPL1, NPL2, and NPL4 are submitted herewith. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of the U.S. patent and the U.S. patent application publication, documents US1 and US2, cited on the attached Form PTO/SB/08A are not submitted.

In addition, a copy of document **NPL3** is not provided in accordance with the U.S. Patent and Trademark Office OG notice of October 19, 2004, which states: "the requirement in 37 C.F.R. § 1.98(a)(2)(iii) for a legible copy of the specification, including the claims, and drawings of each cited pending U.S. patent application (or portion of the application which caused it to be listed) is sua sponte waived where the cited pending application is stored in the USPTO's IFW system."

The Examiner's attention is directed to the following co-pending U.S. Patent Application, which is directed to related technical subject matter:

Application No. 10/843,656, inventors Vilalta, A., et al., filed May 12, 2004, not yet published, cited herein as document **NPL3** on Form PTO/SB/08B.

The identification of this U.S. Patent Application is not to be construed as a waiver of secrecy as to this application now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited applications and the art cited therein during examination.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached Form PTO/SB/08A and Form PTO/SB/08B based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not

Hermanson Appl. No. 10/658,688

exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return copies of the enclosed Form PTO/SB/08A and Form PTO/SB/08B, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Julie A. Heider

Agent for Applicants Registration No. 54,161

Washington, D.C. 20005-3934

1100 New York Avenue, N.W.

(202) 371-2600

424018_1.DOC

Equivalent of Form PTO/SB/08A (07-05)
Approved for use through 07/31/2006.
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE

ubstitute for form 1449/PTO

Sheet

STATEMENT BY APPLICANT (Use as many sheets as necessary)

of

Complete if Known				
Application Number	10/658,688			
Filing Date	September 10, 2003			
First Named Inventor	Gary Hermanson			
Art Unit	1645			
Examiner Name	Baskar, P.			
Attorney Docket Number	1530.0460002/EJH/J-H			

			U.S. PATENT DOCUMENTS	***	
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	
Initials*	No.1	Number-Kind Code ^{2 (If Known)}	MM-DD-YYYY		
	US1	6,875,748 B2	04/05/2005	Manthorpe et al.	
	US2	2004/0209241 A1	10/21/2004	Hermanson et al.	
	-				
		<u> </u>			
	-				
-					
	 				
	<u> </u>				
			FOREIGN PATENT DOCUMEN		
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)			
		1	l		

428349_1.DOC

Examiner	Date
Signature	Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-04) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute fo	Substitute for form 1449/PTO			Complete if Known		
				Application Number	10/658,688	
FIF	FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filing Date	September 10, 2003	
INFO				First Named Inventor	Hermanson	
STAT				Art Unit	1645	
				Examiner Name	Baskar, P.	
Sheet	1	of	1	Attorney Docket Number	1530.0460002/EJH/J-H	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*			
	NPL1	Okinaka, R.T., et al., "Sequence and Organization of pXO1, the Large Bacillus anthracis Plasmid Harboring the Anthrax Toxin Genes," J. Bacteriol. 181:6509-6515, American Society for Microbiology (1999)	
	NPL2	Price, L.B., et al., "Genetic Diversity in the Protective Antigen Gene of Bacillus anthracis," J. Bacteriol. 181:2358-2362, American Society for Microbiology (1999)	
	NPL3	Co-pending U.S. Patent Application No. 10/843,656, inventors Vilalta, A., et al., filed May 12, 2004 (NOT PUBLISHED)	
	NPL4	Hermanson, G., et al., "A Cationic Lipid-Formulated Plasmid DNA Vaccine Confers Sustained Antibody-Mediated Protection Against Aerosolized Anthrax Spores," <i>Proc. Natl. Acad. Sci. USA</i> 101:13601-13606, National Academy of Sciences (2004)	
24012 1 00	^		
24012_1.DO	<u> </u>		

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.